People · Operator

John Nobile

Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology

1
Companies
1
Filings
$28.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Tangen Biosciences, Inc.BiotechnologySeries A$28.4M$4.2M2016
Operator network

John Nobile at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Dan Wagner · 4 companies · 1 sharedDan WagnerChristopher Benoit · 3 companies · 1 sharedChristopher BenoitChristopher McLeod · 3 companies · 1 sharedChristopher McLeodDaniel V. Wagner · 2 companies · 1 sharedDaniel V. WagnerJohn Davidson · 2 companies · 1 sharedJohn DavidsonAlan V. Levin · 1 companies · 1 sharedAlan V. LevinBrian Chirico · 1 companies · 1 sharedBrian ChiricoChristopher V. McLeod · 1 companies · 1 sharedChristopher V. Mc…John Richard Davidson · 1 companies · 1 sharedJohn Richard Davi…John Richard Nobile · 1 companies · 1 sharedJohn Richard Nobi…John V. Davidson · 1 companies · 1 sharedJohn V. DavidsonRichard Birkmeyer, PhD · 1 companies · 1 sharedRichard Birkmeyer…Richard C. Birkmeyer, PhD · 1 companies · 1 sharedRichard C. Birkme…Vance V. Kershner · 1 companies · 1 sharedVance V. KershnerTangen Biosciences, Inc. · $28.4M raisedTangen Biosciences, I…John NobileJN
John Nobile Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside John Nobile on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Dan Wagner14
Christopher McLeod13
Christopher Benoit13
John Davidson12
Daniel V. Wagner12
John Richard Davidson11
Alan V. Levin11
Richard C. Birkmeyer, PhD11
Vance V. Kershner11
Christopher V. McLeod11
John V. Davidson11
Brian Chirico11
Richard Birkmeyer, PhD11
John Richard Nobile11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.